Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monobenzone plus imiquimod for cutaneous melanoma metastases
NL-OMON34176Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2011
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of monobenzone and imiquimod in melanoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical efficacy on cutaneous metastases. Started May 2011; status: active, not recruiting.
02
Drugs
monobenzoneimiquimod
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON34176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34176.